WallStSmart

Bolt Biotherapeutics (BOLT)vsBeOne Medicines AG (ONC)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

BeOne Medicines AG generates 140464% more annual revenue ($6.61B vs $4.70M). ONC leads profitability with a 13.9% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 70/100 (B-).

BOLT

Avoid

29

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 5.0Quality: 5.0
Piotroski: 5/9Altman Z: -12.19

ONC

Strong Buy

70

out of 100

Grade: B-

Growth: 10.0Profit: 7.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 0.75
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BOLT.

ONCUndervalued (+81.0%)

Margin of Safety

+81.0%

Fair Value

$1845.68

Current Price

$411.29

$1434.39 discount

UndervaluedFair: $1845.68Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BOLT1 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

ONC5 strengths · Avg: 9.0/10
Revenue GrowthGrowth
33.8%10/10

Revenue surging 33.8% year-over-year

EPS GrowthGrowth
212.5%10/10

Earnings expanding 212.5% YoY

Debt/EquityHealth
0.209/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.828/10

Growing faster than its price suggests

Operating MarginProfitability
22.2%8/10

Strong operational efficiency at 22.2%

Areas to Watch

BOLT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.33M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

ONC3 concerns · Avg: 2.7/10
Price/BookValuation
8.1x4/10

Trading at 8.1x book value

P/E RatioValuation
52.2x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.752/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BOLT

The strongest argument for BOLT centers on Price/Book.

Bull Case : ONC

The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 33.8% demonstrates continued momentum. PEG of 0.82 suggests the stock is reasonably priced for its growth.

Bear Case : BOLT

The primary concerns for BOLT are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 1.71 is elevated, increasing financial risk.

Bear Case : ONC

The primary concerns for ONC are Price/Book, P/E Ratio, Altman Z-Score. A P/E of 52.2x leaves little room for execution misses.

Key Dynamics to Monitor

BOLT profiles as a value stock while ONC is a growth play — different risk/reward profiles.

BOLT carries more volatility with a beta of 1.01 — expect wider price swings.

ONC is growing revenue faster at 33.8% — sustainability is the question.

ONC generates stronger free cash flow (474M), providing more financial flexibility.

Bottom Line

ONC scores higher overall (70/100 vs 29/100) and 33.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bolt Biotherapeutics

HEALTHCARE · BIOTECHNOLOGY · USA

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the discovery, development and commercialization of pharmaceutical products. The company is headquartered in Redwood city, California.

Visit Website →

BeOne Medicines AG

HEALTHCARE · BIOTECHNOLOGY · USA

BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.

Visit Website →

Want to dig deeper into these stocks?